OncoSec Medical Inc (ONCSQ)

[hschlauch]

Perhaps the key differentiating features are these:

1) Electroporating devices - I think what sets ONCS apart is their new real time and adaptive technology that theoretically works with any tumor type anywhere in the body. Each pulse duration is optimized based on feedback data. Their helical needle seems to offer improvements in terms of surface area coverage as well. If all of this is indeed true, then there should be improvements on efficiencies and efficacies.

2) ONCS's proposed multigene product, to be used with their new EP technology, should address a greater suite of biological pathways in the tumor microenvironment. I think the proposed multigene product will demonstrate improvements in terms of the number of antigen-specific and pd-1-positive tumor infiltrating lymphocytes, and will likely allow more tumor cells to upregulate pdl1; this would allow for a more robust response once the EP mAbs are expressed. I don't see Inovio pursuing such an aggressive immune response platform. Inovio is using EP DNA encoded constructs for IL-12, antigens, and various mAbs, but they don't appear to be generating TLR, additional chemokines, antigen chaperones, APC, or co-stimulatory molecules.

Inovio is accomplishing great things in my opinion, but the subtle differences between the companies might be enough to differentiate the better choice in terms of cancer applications. Also, they don't seem to be pursuing the same disease indications thus far.

One additional point - ONCS still needs to produce preclinical data for the combination of their multigene product, the new EP device, and EP DNA encoded mAb constructs.